By Topic

QT Variability Index Changes With Severity of Cardiovascular Autonomic Neuropathy

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

5 Author(s)
Khandoker, A.H. ; Dept. of Electr. & Electron. Eng., Univ. of Melbourne, Melbourne, VIC, Australia ; Imam, M.H. ; Couderc, J. ; Palaniswami, M.
more authors

Cardiovascular autonomic neuropathy (CAN) has been frequently postulated to increase susceptibility to ventricular arrhythmias and sudden cardiac death in diabetic patients. The relation between the progression of CAN in diabetes and ventricular repolarization remains to be fully described. Therefore, this study examined QT interval variability and heart rate interbeat variability to identify any alterations of cardiac repolarization in diabetic patients in relation to severity of CAN. Seventy control participants without (CAN-) and 74 patients with CAN (CAN+) were enrolled in this study. Among 74 CAN+ patients, 62 are early CAN+ (eCAN+) , and 12 are definite CAN+ (dCAN+) according to autonomic nervous system function tests as described by Ewing. The results showed that the QT variability index (QTVI) was significantly (p <; 0.05) higher and positive in the dCAN+ (0.51 ±1.32) group than in the eCAN+ (-0.39 ±0.91) and CAN - (-0.54 ±0.72) groups. The QT variability to heart-rate variability ratio provides a measure of the balance between QT and heart interbeat variability. QTVI was more sensitive in identifying disease progression at all stages. Our study supports the hypothesis that QTVI could be used as a clinical test to identify early CAN and as a marker of CAN progression in diabetic patients and may help physicians in determining the best therapeutic strategy for these patients.

Published in:

Information Technology in Biomedicine, IEEE Transactions on  (Volume:16 ,  Issue: 5 )